$SGMO
SANGAMO THERAPEUTICS, INC

2017 Q1 Form 10-Q Financial Statement

#000156459017010305 Filed on May 10, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q1
Revenue $3.425M $3.942M
YoY Change -13.12% -70.78%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.280M $5.360M
YoY Change 35.82% 13.32%
% of Gross Profit
Research & Development $12.94M $15.27M
YoY Change -15.22% 1.91%
% of Gross Profit
Depreciation & Amortization $301.0K $245.0K
YoY Change 22.86% 66.67%
% of Gross Profit
Operating Expenses $20.22M $20.62M
YoY Change -1.97% 4.62%
Operating Profit -$16.79M -$16.68M
YoY Change 0.67% 168.14%
Interest Expense $160.0K $190.0K
YoY Change -15.79% 26.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$16.63M -$16.49M
YoY Change 0.82% 171.86%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$16.63M -$16.49M
YoY Change 0.84% 210.1%
Net Earnings / Revenue -485.61% -418.42%
Basic Earnings Per Share
Diluted Earnings Per Share -$234.1K -$234.3K
COMMON SHARES
Basic Shares Outstanding 70.88M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $129.3M $188.6M
YoY Change -31.44% -16.45%
Cash & Equivalents $18.49M $33.01M
Short-Term Investments $110.8M $155.6M
Other Short-Term Assets $1.700M $600.0K
YoY Change 183.33% -40.0%
Inventory
Prepaid Expenses
Receivables $2.400M $2.600M
Other Receivables $400.0K $400.0K
Total Short-Term Assets $133.8M $191.1M
YoY Change -29.98% -6.28%
LONG-TERM ASSETS
Property, Plant & Equipment $7.300M $3.200M
YoY Change 128.13% 6.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.000M $1.000M
YoY Change 200.0% -96.64%
Other Assets $1.200M $100.0K
YoY Change 1100.0% -36.31%
Total Long-Term Assets $13.00M $5.900M
YoY Change 120.34% -82.95%
TOTAL ASSETS
Total Short-Term Assets $133.8M $191.1M
Total Long-Term Assets $13.00M $5.900M
Total Assets $146.8M $197.0M
YoY Change -25.48% -17.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.400M $3.100M
YoY Change 138.71% -54.41%
Accrued Expenses $2.000M $1.700M
YoY Change 17.65% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.10M $10.10M
YoY Change 29.7% -49.42%
LONG-TERM LIABILITIES
Long-Term Debt $3.900M $200.0K
YoY Change 1850.0%
Other Long-Term Liabilities $4.100M $7.300M
YoY Change -43.84% -33.64%
Total Long-Term Liabilities $8.000M $7.500M
YoY Change 6.67% -31.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.10M $10.10M
Total Long-Term Liabilities $8.000M $7.500M
Total Liabilities $21.10M $17.60M
YoY Change 19.89% -43.26%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $125.7M $179.4M
YoY Change
Total Liabilities & Shareholders Equity $146.8M $197.0M
YoY Change -25.48% -17.4%

Cashflow Statement

Concept 2017 Q1 2016 Q1
OPERATING ACTIVITIES
Net Income -$16.63M -$16.49M
YoY Change 0.84% 210.1%
Depreciation, Depletion And Amortization $301.0K $245.0K
YoY Change 22.86% 66.67%
Cash From Operating Activities -$13.10M -$20.40M
YoY Change -35.78% 750.0%
INVESTING ACTIVITIES
Capital Expenditures $468.0K $252.0K
YoY Change 85.71% -76.75%
Acquisitions
YoY Change
Other Investing Activities $6.500M -$16.00M
YoY Change -140.63% -182.05%
Cash From Investing Activities $6.100M -$16.30M
YoY Change -137.42% -188.59%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $23.00K $187.0K
YoY Change -87.7% -94.12%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.400M 200.0K
YoY Change 1600.0% -93.75%
NET CHANGE
Cash From Operating Activities -13.10M -20.40M
Cash From Investing Activities 6.100M -16.30M
Cash From Financing Activities 3.400M 200.0K
Net Change In Cash -3.600M -36.50M
YoY Change -90.14% -290.1%
FREE CASH FLOW
Cash From Operating Activities -$13.10M -$20.40M
Capital Expenditures $468.0K $252.0K
Free Cash Flow -$13.57M -$20.65M
YoY Change -34.3% 492.77%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
301000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-16632000
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-16792000
CY2017Q1 us-gaap Revenues
Revenues
3425000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12942000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7275000
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
20217000
CY2017Q1 us-gaap Interest And Other Income
InterestAndOtherIncome
160000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
71025000
CY2017Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-112000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16744000
CY2017Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-60000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2788000
CY2017Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-72000
CY2017Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
174000
CY2016Q1 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
95000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2571000
CY2017Q1 sgmo Net Proceeds From Issuance Public Offering
NetProceedsFromIssuancePublicOffering
3425000
CY2017Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4000
CY2016Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2000
CY2016Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
253000
CY2017Q1 sgmo License Included In Accrued Liabilities
LicenseIncludedInAccruedLiabilities
950000
CY2016Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
46000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-70000
CY2016Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-172000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-418000
CY2016Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5158000
CY2017Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-846000
CY2016Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1026000
CY2017Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-870000
CY2016Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1224000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13078000
CY2016Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-20360000
CY2017Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
38973000
CY2016Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
84816000
CY2017Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45500000
CY2016Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
68770000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
468000
CY2016Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
252000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
6059000
CY2016Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-16298000
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
23000
CY2016Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
187000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3444000
CY2016Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
185000
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3575000
CY2016Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-36473000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69482000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33009000
CY2017Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
536000
CY2014Q1 sgmo Number Of Research Program
NumberOfResearchProgram
2
CY2017Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</p></div>
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2788000
CY2016Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3194000
CY2015Q4 sgmo Build To Suit Lease Property Leased
BuildToSuitLeasePropertyLeased
41400
CY2017Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2016-12-31
CY2015Q4 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P5Y
CY2015Q4 sgmo Operating Leases Number Of Extension Options
OperatingLeasesNumberOfExtensionOptions
2
CY2017Q1 sgmo Build To Suit Lease Costs Capitalized
BuildToSuitLeaseCostsCapitalized
3900000
CY2017Q1 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2017Q1 sgmo Assets Amortized Cost
AssetsAmortizedCost
124469000
CY2016Q4 sgmo Assets Amortized Cost
AssetsAmortizedCost
139416000
CY2017Q1 sgmo Assets Accumulated Gross Unrealized Gain Before Tax
AssetsAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2016Q4 sgmo Assets Accumulated Gross Unrealized Gain Before Tax
AssetsAccumulatedGrossUnrealizedGainBeforeTax
76000
CY2017Q1 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
63000
CY2016Q4 sgmo Assets Accumulated Gross Unrealized Loss Before Tax
AssetsAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2017Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
124407000
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
139466000
CY2017Q1 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
CY2016Q4 sgmo Other Than Temporarily Impaired Investment
OtherThanTemporarilyImpairedInvestment
0
CY2017Q1 sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P2Y
CY2016 sgmo Investments Maturity Dates Available For Sale Securities
InvestmentsMaturityDatesAvailableForSaleSecurities
P2Y
CY2017Q1 us-gaap Available For Sale Securities Gross Realized Losses
AvailableForSaleSecuritiesGrossRealizedLosses
0

Files In Submission

Name View Source Status
0001564590-17-010305-index-headers.html Edgar Link pending
0001564590-17-010305-index.html Edgar Link pending
0001564590-17-010305.txt Edgar Link pending
0001564590-17-010305-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sgmo-10q_20170331.htm Edgar Link pending
sgmo-20170331.xml Edgar Link completed
sgmo-20170331.xsd Edgar Link pending
sgmo-20170331_cal.xml Edgar Link unprocessable
sgmo-20170331_def.xml Edgar Link unprocessable
sgmo-20170331_lab.xml Edgar Link unprocessable
sgmo-20170331_pre.xml Edgar Link unprocessable
sgmo-ex101_7.htm Edgar Link pending
sgmo-ex102_6.htm Edgar Link pending
sgmo-ex103_10.htm Edgar Link pending
sgmo-ex104_8.htm Edgar Link pending
sgmo-ex311_12.htm Edgar Link pending
sgmo-ex312_9.htm Edgar Link pending
sgmo-ex321_11.htm Edgar Link pending
Show.js Edgar Link pending